US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Roche Holding Ltd

40.42

-0.2800-0.69%

Volume:1.24M

Turnover:50.17M

Market Cap:261.68B

PE:26.06

High:40.60

Open:40.49

Low:40.25

Close:40.70

Loading ...

Overview Company News Filings

Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma

Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug

SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?

Roche CEO says no plans for job cuts, business healthy, Reuters reports

Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why

RBC sees justification for Prothena rebound after study miss

SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder

Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study -- Update

Roche announces PADOVA study misses statistical significance

Roche's Negative Parkinson Drug Results Don't Surprise -- Market Talk

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases

Swiss Equities an Overweight Pick Next Year -- Market Talk

Regeneron Down 15.5% Year to Date: How to Play the Stock?

Genentech presents updated fixed-duration Columvi and Lunsumio data at ASH

Roche Holding AG Rises Monday, Outperforms Market

Roche says five-year results confirm Polivy combo as ‘new standard of care’

Stock Market Rallies On: AI Software, Biotechs, Costco Coming Up

Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ

FDA Accepts Roche's Columvi sBLA for Expanded Use in Lymphoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RHHBY/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"Roche Holding Ltd","latestPrice":40.42,"timestamp":1746640740000,"preClose":40.7,"halted":0,"volume":1240861,"delay":15,"floatShares":6374000000,"shares":6474029800,"eps":1.550894,"marketStatus":"Trading","change":-0.28,"latestTime":"05-07 13:59:00 EDT Delay","open":40.49,"high":40.6,"low":40.25,"amount":50167877.457873,"amplitude":0.0086,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746648000000},"marketStatusCode":2,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":40.7,"volumeRatio":0.72194},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6374000000,"roa":"12.75%","roe":"26.47%","lyrEps":2.136203,"volumeRatio":0.72194,"shares":6474029800,"dividePrice":1.477462,"high":40.6,"amplitude":0.0086,"preClose":40.7,"low":40.25,"week52Low":30.06,"pbRate":"6.76","psRate":"3.44","week52High":44.31,"institutionHeld":0,"latestPrice":40.42,"eps":1.550894,"divideRate":0.036553,"volume":1240861,"delay":15,"ttmEps":1.550894,"open":40.49,"prevYearClose":34.88,"prevWeekClose":41.08,"prevMonthClose":40.77,"prevQuarterClose":41.15,"fiveDayClose":40.77,"twentyDayClose":35.9,"sixtyDayClose":39.88},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503321752","title":"Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2503321752","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503321752?lang=en_us&edition=fundamental","pubTime":"2025-01-13 14:00","pubTimestamp":1736748000,"startTime":"0","endTime":"0","summary":"The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation  test with the sensitivity to assess the full spectrum of B-cell lymphoma subtypes.1,2. The test helps differentiate a B-cell cancer from a normal, reactive immune response, offering diagnostic certainty for healthcare providers and their patients.B-cell lymphoma accounts for approximately 85 percent of non-Hodgkin lymphoma  cases, which is one of the most common cancers in the US.3. TUCSON, Ariz., Jan. 13, 2025 /PRNewswire/ -- Roche  announced today that it has received 510 clearance from the United States Food and Drug Administration  for its highly-sensitive in-situ hybridisation  test, the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail.4 The test is designed to help pathologists differentiate a B-cell malignancy from a normal, reactive response to an infection, thus facilitating faster access to treatment.4 This announcement follows the assay's CE Mark appro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/roche-receives-fda-clearance-highly-060000655.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roche-receives-fda-clearance-highly-060000655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4148","RHHBY","BK4007","03165","ROG"],"gpt_icon":0},{"id":"2502601486","title":"Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2502601486","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502601486?lang=en_us&edition=fundamental","pubTime":"2025-01-09 19:19","pubTimestamp":1736421540,"startTime":"0","endTime":"0","summary":"Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and efficacy of the oral version of its investigational obesity drug VK2735.This study's primary endpoint is the percent change in body weight from baseline after 13 weeks of treatment. Management plans to enroll around 280 adults who are either obese or overweight and have at least one weight-related co-morbid condition. These patients will be evenly randomized to one of the six dosing arms of the drug or placebo.The study initiation is supported by data from a phase I study, which showed that patients who were administered the drug lost up to 8.2% of theirbody weight after 28 days of daily dosing compared with 1.4% in the placebo group. All patients who took the highest drug dose lost at least 5% of their body weight.VKTX Provides Update on Injectable Version of Obesity Drug. Alongside the above news, Viking Therapeutics also announced that it plans to start a late-sta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viking-therapeutics-starts-mid-stage-111900314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1127390331.HKD","SG9999014906.USD","LU1988902786.USD","LU1868836757.USD","IE0009355771.USD","LU2023250504.SGD","NVO","SG9999014880.SGD","LU1868837136.USD","LU2237443978.SGD","LU0122379950.USD","LU0203201768.USD","SSI","LU2491049909.HKD","IE00BJJMRZ35.SGD","LU2237438978.USD","RHHBY","LU0114720955.EUR","BK4585","AMGN","LU0471298777.SGD","IE00B4R5TH58.HKD","LU1989771016.USD","LLY","LU1804176565.USD","SG9999015986.USD","LU1291159041.SGD","03165","BK4007","LU0882574139.USD","LU1267930730.SGD","LU0238689110.USD","BK4516","IE0002141913.USD","SGXZ51526630.SGD","LU0640476718.USD","SG9999018865.SGD","LU0456855351.SGD","LU2063271972.USD","LU2324357040.USD","LU2468319806.SGD","LU2491050154.USD","LU0096364046.USD","SG9999015945.SGD","LU1868836914.USD","IE00BK4W5M84.HKD","SGXZ57979304.SGD","VKTX","SG9999018857.SGD","LU2237443895.HKD","IE0004445239.USD"],"gpt_icon":1},{"id":"2501230924","title":"SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?","url":"https://stock-news.laohu8.com/highlight/detail?id=2501230924","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501230924?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:40","pubTimestamp":1736167200,"startTime":"0","endTime":"0","summary":"Shares of Sarepta Therapeutics SRPT have risen 23% in the past year, significantly outperforming the industry’s 15.7% decline, as shown in the chart below. During this timeframe, the stock has also outdone the broader Medical sector but slightly underperformed the S&P 500 Index. SRPT’s shares are trading above the 50-day moving average.The surge in the stock price can be attributed to the encouraging sales performance of Sarepta’s Duchenne muscular dystrophy  gene therapy Elevidys.Let’s delve into the company’s strengths and weaknesses to gain a better understanding of how to play the stock amid the price surge.Elevidys has been developed by Sarepta in partnership with pharma big-wig Roche RHHBY. Per a licensing deal signed in 2019, RHHBY has exclusive rights to launch and market Elevidys in ex-U.S. markets. Sarepta started recording royalty revenues from ex-U.S. sales of the therapy in the third quarter of 2024. During the quarter, Sarepta received $9.5 million from Roche as royalty r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-stock-rises-23-time-124000929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SRPT","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4585","03165","BK4139","IE0009355771.USD","BK4007","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","RHHBY"],"gpt_icon":0},{"id":"2495532087","title":"Roche CEO says no plans for job cuts, business healthy, Reuters reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2495532087","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495532087?lang=en_us&edition=fundamental","pubTime":"2024-12-30 05:25","pubTimestamp":1735507505,"startTime":"0","endTime":"0","summary":"Swiss pharmaceutical company Roche (RHHBY) is not planning job cuts and its business is healthy, CEO Thomas Schinecker was quoted as saying by a Sw...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-ceo-says-no-plans-for-job-cuts-business-healthy-reuters-reports?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-ceo-says-no-plans-for-job-cuts-business-healthy-reuters-reports?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","03165","RHHBY"],"gpt_icon":0},{"id":"2494335850","title":"Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2494335850","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494335850?lang=en_us&edition=fundamental","pubTime":"2024-12-27 23:10","pubTimestamp":1735312200,"startTime":"0","endTime":"0","summary":"Shares of Puma Biotechnology, Inc. PBYI have rallied 24% in the past three months against the industry’s decline of 9.7%.The company’s sole marketed product, Nerlynx , is approved for treating early-stage HER2-positive breast cancer in patients previously treated with Roche’s RHHBY Herceptin-based adjuvant therapy.In the first nine months of 2024, Nerlynx generated sales worth $140.8 million. Sales of the drug improved in the third quarter of 2024 and came ahead of management’s expectations.Owing to the better-than-expected sales, PBYI updated its financial guidance for 2024 during the third quarter of 2024. The company now expects Nerlynx’s product sales to be in the range of $187-$190 million in 2024, compared with the earlier projection of $183-$190 million.The improved sales of Nerlynx have been the primary reason for the stock’s increase during the said time.PBYI expects Nerlynx product sales to be in the band of $46-$48 million in the fourth quarter of 2024. It remain","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/puma-biotechnology-stock-rises-24-151000280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMCR","BK4139","SPRO","BK4505","PBYI","RHHBY","03165","BK4007"],"gpt_icon":0},{"id":"2492101245","title":"RBC sees justification for Prothena rebound after study miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2492101245","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492101245?lang=en_us&edition=fundamental","pubTime":"2024-12-20 01:20","pubTimestamp":1734628832,"startTime":"0","endTime":"0","summary":"RBC Capital keeps a Sector Perform rating on Prothena (PRTA) after the company’s partner Roche (RHHBY) presented topline data from the Phase IIb PA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rbc-sees-justification-for-prothena-rebound-after-study-miss?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rbc-sees-justification-for-prothena-rebound-after-study-miss?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRTA","BK4139","BK4207","RHHBY","03165","BK4007"],"gpt_icon":0},{"id":"2492174258","title":"SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2492174258","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492174258?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:45","pubTimestamp":1734615900,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics SRPT announced that it has completed enrolment and dosing in the phase III EMERGENE study evaluating its investigational gene therapy, SRP-9003  for treating limb-girdle muscular dystrophy  Type 2E/R4 .Data from the EMERGENE study is expected in the first half of 2025. If the data is positive, Sarepta intends to submit a regulatory filing seeking accelerated approval for SRP-9003 in the given indication before the end of next year.The primary endpoint of the study is the biomarker expression of the beta-sarcoglycan protein, whose absence is the sole cause of the disease.LGMD2E/R4 is an ultra-rare form of LGMD for which there is no treatment beyond symptom management. Patients suffering from this genetic disease exhibit neuromuscular symptoms, which include difficulty in running, jumping and climbing stairs, before the age of 10. Because of the lack of treatments, the disease often progresses to loss of mobility during the teenage years and is associated with early ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2ZuhDuDie_37lq4aVERX2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4718122d03716403704541c667907c4e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2ZuhDuDie_37lq4aVERX2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4718122d03716403704541c667907c4e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-finishes-enrolment-stage-study-134500600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJJMRZ35.SGD","03165","IE0002141913.USD","RHHBY","BK4139","CSTL","CTMX","IE00BJT1NW94.SGD","BK4196","BK4007","SSI","IE0009355771.USD","IE00BFTCPJ56.SGD","SRPT","BK4585","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2492127445","title":"Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2492127445","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492127445?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:05","pubTimestamp":1734613500,"startTime":"0","endTime":"0","summary":"Roche said a Parkinson's disease experimental drug missed its primary goal in a mid-stage trial, the second setback this week for candidate treatments for the neurodegenerative condition.The update from the Swiss pharmaceutical giant came after Belgian peer UCB said a similar drug candidate for Parkinson's developed jointly with Novartis failed to meet key goals in a clinical trial.Roche said Thursday that its drug candidate, prasinezumab, didn't delay progression of motor symptoms in the trial, which included early-stage Parkinson's patients, to an extent considered statistically significant.However, the company said the drug did show potential clinical efficacy, as well as positive trends on several other goals of the trial, and was well tolerated. Roche will continue to evaluate the data and work together with health authorities to decide on next steps, it said.\"We believe the consistent efficacy trends from the Phase IIb study of prasinezumab merit further exploration,\" Roche's Chi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSI","03165","BK4007","RHHBY"],"gpt_icon":0},{"id":"2492147559","title":"Roche announces PADOVA study misses statistical significance","url":"https://stock-news.laohu8.com/highlight/detail?id=2492147559","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492147559?lang=en_us&edition=fundamental","pubTime":"2024-12-19 18:10","pubTimestamp":1734603057,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson’s disease, trea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-announces-padova-study-misses-statistical-significance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-announces-padova-study-misses-statistical-significance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RHHBY","BK4007","03165"],"gpt_icon":0},{"id":"2492143811","title":"Roche's Negative Parkinson Drug Results Don't Surprise -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2492143811","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492143811?lang=en_us&edition=fundamental","pubTime":"2024-12-19 16:10","pubTimestamp":1734595800,"startTime":"0","endTime":"0","summary":"0810 GMT - Roche's negative Parkinson trial readout doesn't surprise as the drug candidate had a high development risk all along, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's experimental Parkinson drug prasinezumab showed a numeric delay in slowing motor progression in early-stage Parkinson patients but still missed its primary goal in a mid-stage study. Vontobel estimated potential annual peak sales for 2.5 billion Swiss francs for prasinezumab which it didn't account for in its forecasts due to the high development risk associated with this drug, the analyst says. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","BK4007","03165"],"gpt_icon":0},{"id":"2492866626","title":"Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2492866626","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492866626?lang=en_us&edition=fundamental","pubTime":"2024-12-17 06:03","pubTimestamp":1734386580,"startTime":"0","endTime":"0","summary":"The end of Novo Nordisk's supply problems could bring new headaches for the rest of the pharmaceutical industry, which now has to consider what it means to outsource its manufacturing to a company that owns a major competitor.Novo says that it has regulatory clearance to buy three key manufacturing sites used to make drugs like Wegovy, its blockbuster obesity medicine. That could ease the supply shortages that have dogged the launch of Wegovy and its sister drug, the Type 2 diabetes treatment Ozempic. However, the acquisition of the sites is part of a larger deal that could bring a reordering of the pharmaceutical industry.When the dust has settled, Novo will own three highly specialized facilities formerly owned by Catalent that do the difficult, finicky work involved in the last steps of manufacturing Wegovy and similar drugs. Novo has said it will \"honour all customer obligations\" at those three sites.Lilly shares closed 1.3% lower at $779.02 on Monday. In an August earnings call, t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0011850046.USD","LU1720051017.SGD","LU0109391861.USD","LU0122379950.USD","03165","LU0234572021.USD","LU1917777945.USD","LU2468319806.SGD","IE0004445239.USD","LU0471298694.HKD","LU2023250504.SGD","SG9999001176.SGD","RHHBY","LU0320765059.SGD","LU0354030511.USD","LU1551013342.USD","BK4548","LU1366192091.USD","LU2720916845.USD","LU1267930730.SGD","LU2237443622.USD","LU2264538146.SGD","LU0882574055.USD","LU0061474960.USD","LU1057294990.SGD","IE0002141913.USD","LU1854103824.USD","LU2041044095.USD","LU1061106388.HKD","LU0238689110.USD","CTLT","BK4007","LU1791710400.SGD","LU2237443549.SGD","LLY","TMO","IE00B19Z8W00.USD","LU1633808545.USD","IE00BJJMRZ35.SGD","SG9999018865.SGD","LU0354030438.USD","IE00BJLML261.HKD","LU0094547139.USD","LU2237443382.USD","LU1791710582.SGD","LU1868836591.USD","LU1815333072.USD","BK4533","LU2360106947.USD","SG9999018857.SGD"],"gpt_icon":1},{"id":"2492647708","title":"Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2492647708","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492647708?lang=en_us&edition=fundamental","pubTime":"2024-12-17 02:40","pubTimestamp":1734374400,"startTime":"0","endTime":"0","summary":"Roche RHHBY announced that the European Medicines Agency has approved a prefilled syringe  of the ophthalmology drug Vabysmo .The regulatory body approved Vabysmo PFS for use in the treatment of neovascular or ‘wet’ age-related macular degeneration , diabetic macular edema  and macular edema following retinal vein occlusion .In the past three months, shares of Roche have lost 9.1% compared with the industry’s 14.3% decline.The approval of the Vabysmo prefilled syringe in the EU offers a convenient way to administer this leading ophthalmology treatment for people with three of the most common causes of vision loss.These three conditions — nAMD , DME and RVO — affect more than 9 million people in the EU.The PFS delivers the same drug as the currently available 6.0 mg Vabysmo vials in an alternative, ready-to-use format.Per Roche, Vabysmo PFS will be the EU’s first and only prefilled syringe containing a bispecific antibody to treat retinal conditions that can cause blindness.Over the pas","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YaeP6YMQifV47czKTk1orA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YaeP6YMQifV47czKTk1orA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roche-gets-approval-vabysmo-pfs-184000806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0306807586.USD","03165","LU1917777945.USD","LU1093756168.USD","LU0053666078.USD","LU2106854487.HKD","LU1032466523.USD","LU1066053197.SGD","RHHBY","LU1670711123.USD","IE00BKVL7J92.USD","LU0823416689.USD","LU1074936037.SGD","REGN","BK4559","LU1868837136.USD","IE00B2B36J28.USD","LU0985481810.HKD","BK4139","LU0225771236.USD","LU2242646821.SGD","PFS","LU2362541513.USD","LU0234570918.USD","IE00BFTCPJ56.SGD","LU1718418525.SGD","IE0002141913.USD","GILD","BK4585","LU0109394709.USD","LU1868836757.USD","LU0225284248.USD","LU0289739699.SGD","LU1974910355.USD","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","LU0868494617.USD","IE00BJJMRZ35.SGD","BMY","IE00BZ1G4Q59.USD","IE0009355771.USD","BK4211","LU2087621335.USD","LU1670711040.USD","LU2360032135.SGD","BK4550","LU1868836914.USD","LU1670710588.SGD"],"gpt_icon":0},{"id":"2491370859","title":"Swiss Equities an Overweight Pick Next Year -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2491370859","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491370859?lang=en_us&edition=fundamental","pubTime":"2024-12-14 00:36","pubTimestamp":1734107760,"startTime":"0","endTime":"0","summary":"1636 GMT - Bank of America is overweight on Swiss equities for 2025 in part because the country is heavy on the bank's defensive sector picks of food and pharma, analysts say in a research note on European equity strategy. \"Owing to its defensive sector overweight, the Swiss market tends to outperform when global PMI momentum is negative, as we expect it to be for most of next year,\" BofA analysts say. Switzerland has underperformed the broader European market by 15% over the past two years, they note. Among Swiss large caps, food giant Nestle's shares are down more than 20% year-to-date, while pharma heavyweights Roche and Novartis have made just single-digit gains. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","NSRGY","NVS"],"gpt_icon":0},{"id":"2491537198","title":"Regeneron Down 15.5% Year to Date: How to Play the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2491537198","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491537198?lang=en_us&edition=fundamental","pubTime":"2024-12-13 22:09","pubTimestamp":1734098940,"startTime":"0","endTime":"0","summary":"Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.The stock has underperformed the sector and the S&P 500 Index during this timeframe. While the stock’s performance was encouraging at the onset of 2024, challenges for lead drug Eylea have dampened investors’ sentiment of late.Eylea is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications.Regeneron has a collaboration agreement with Bayer BAYRY for Eylea. Regeneron records the net product sales of Eylea and Eylea HD in the United States, and Bayer records its net product sales outside the country. Regeneron records its share of profits in connection with Eylea’s sales outside the United States.REGN’s oncology franchise got a boost with the European Commission's approval of odronextamab for treating adult patients with relapsed or refractory (R/R) follicular lymphoma  or R/R diffuse large B-cell lymphoma after two","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-down-15-5-date-140900718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FL","LU0889565916.HKD","LU0390134368.USD","LU1917777945.USD","LU0823416689.USD","LU0320765992.SGD","IE00BFXG1179.USD","SNY","LU2468319806.SGD","LU2362541273.HKD","LU2362541513.USD","BK4007","BK4121","LU1974910355.USD","BAYRY","BK4530","BK4585","BK4588","BK4139","RHHBY","LU2362540622.SGD","LU2089984988.USD","REGN","CRL","LU0053666078.USD","LU2106854487.HKD","LU0109394709.USD","LU0058720904.USD","LU0114720955.EUR","LU0289739699.SGD","BK4094","LU0882574055.USD","03165","LU2023250504.SGD"],"gpt_icon":0},{"id":"2490035813","title":"Genentech presents updated fixed-duration Columvi and Lunsumio data at ASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2490035813","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490035813?lang=en_us&edition=fundamental","pubTime":"2024-12-10 08:40","pubTimestamp":1733791210,"startTime":"0","endTime":"0","summary":"The company states: “Genentech, a member of the Roche (RHHBY) Group, announced that new and updated data from its industry-leading CD20xCD3 T-cell-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genentech-presents-updated-fixed-duration-columvi-and-lunsumio-data-at-ash?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genentech-presents-updated-fixed-duration-columvi-and-lunsumio-data-at-ash?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2463526074.USD","03165","RHHBY","BK4109","BK4007","ASH"],"gpt_icon":0},{"id":"2490708294","title":"Roche Holding AG Rises Monday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2490708294","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490708294?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:16","pubTimestamp":1733764560,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  rose 0.1% to CHF257.20 Monday on what proved to be an overall negative trading session for the stock market, with the Swiss SMI Index  falling 0.2% to 11,761.72.This was the stock's third consecutive day of gains.Roche Holding AG closed CHF31.00 short of its 52-week high of CHF288.20, which the company achieved on September 2, 2024.Trading volume was 749,156, compared to the 50-day average trading volume of 1,083,204.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","AG"],"gpt_icon":0},{"id":"2490754647","title":"Roche says five-year results confirm Polivy combo as ‘new standard of care’","url":"https://stock-news.laohu8.com/highlight/detail?id=2490754647","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490754647?lang=en_us&edition=fundamental","pubTime":"2024-12-09 04:05","pubTimestamp":1733688313,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced data from a five-year follow-up of the pivotal Phase 3 POLARIX study evaluating Polivy in combination with MabThera/Rituxan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-says-five-year-results-confirm-polivy-combo-as-new-standard-of-care?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-says-five-year-results-confirm-polivy-combo-as-new-standard-of-care?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","03165","RHHBY"],"gpt_icon":0},{"id":"2489674932","title":"Stock Market Rallies On: AI Software, Biotechs, Costco Coming Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2489674932","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489674932?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:59","pubTimestamp":1733522386,"startTime":"0","endTime":"0","summary":"The stock market's holiday mood could continue in the coming week, as Oracle leads AI software names and Costco covers the retail angle.","market":"hk","thumbnail":"https://www.investors.com/wp-content/uploads/2020/12/Stock-ChristmasTree-NYSE-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2020/12/Stock-ChristmasTree-NYSE-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/investing-action-plan/stock-market-ai-software-oracle-biotechs-costco-earnings/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["NVDS","CASY","EME.AU","LU0348825331.USD","RHHBY","NVDA","TCOM","US7Y.BOND","MDB","NVDU","US12M.BOND","US3Y.BOND","LU1153585028.USD","LU0345768153.USD","NVDX","ORCL","AMGN","AZO","2NVD.UK","3NVD.UK","SNVD.UK","BLK","NVD2.UK","US6M.BOND","ADBE","COST","US10Y.BOND","INCY","US5Y.BOND","TRV","03165","NVDD","BEAM","LU1334329650.SGD","LEN","NVD3.UK","NVDY","US30Y.BOND","EME","NVD","NVDS.UK","BLK.AU","TOL","US2Y.BOND","LU1430594728.SGD","UNFI","NVS","GILD"],"gpt_icon":1},{"id":"2489231752","title":"Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2489231752","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489231752?lang=en_us&edition=fundamental","pubTime":"2024-12-06 21:11","pubTimestamp":1733490660,"startTime":"0","endTime":"0","summary":"This week, Eli Lilly’s LLY popular obesity drug, Zepbound showed better weight loss than Novo Nordisk’s Wegovy in a head-to-head study. The FDA granted Breakthrough Therapy designation to Merck’s MRK candidate sacituzumab tirumotecan for a lung cancer indication and approved AstraZeneca’s AZN blockbuster cancer drug, Imfinzi for a new indication. The FDA also accepted Roche’s RHHBY supplemental filing seeking expanded use of its drug, Columvi. J&J JNJ also filed an application with the FDA, seeking approval of Tremfya for children.Here's a recap of the week’s most important stories.LLY’s Zepbound Outperforms NVO’s Wegovy in Weight Loss Study. The FDA granted approval to AstraZeneca’s Imfinzi for treating limited-stage small cell lung cancer , an aggressive form of lung cancer, in the United States. The approval was based on data from the ADRIATIC phase III study for LS-SCLC patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-llys-zepbound-131100794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["JNJ","SG9999017495.SGD","LU0795875169.SGD","ADC","LU1116320737.USD","LU1934455277.USD","LU0320765489.SGD","SG9999001440.SGD","AZN","SG9999015945.SGD","IE00B19Z3581.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","03165","LU1066051225.USD","LU0094547139.USD","SG9999018865.SGD","LU0889566641.SGD","IE00BK4W5M84.HKD","LU2237443622.USD","LU0203347892.USD","LU1551013425.SGD","LU1261432733.SGD","IE00BK4W5L77.USD","LU1941712264.USD","LU2602419157.SGD","SG9999014575.USD","LU0882574055.USD","LU0122379950.USD","LU2237443382.USD","LU1221951046.USD","MRK","LU0096364046.USD","BK4533","LU0109391861.USD","LU0820561909.HKD","LU0861579265.USD","LU2462157665.USD","LU2491050154.USD","RHHBY","LU0345769128.USD","LU0965509283.SGD","LU2063271972.USD","LU1066051811.HKD","LLY","LU0320765646.SGD","LU1935042991.SGD","LU1983299246.USD","LU1894683348.USD","LU1551013342.USD"],"gpt_icon":1},{"id":"2489245032","title":"FDA Accepts Roche's Columvi sBLA for Expanded Use in Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2489245032","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489245032?lang=en_us&edition=fundamental","pubTime":"2024-12-05 21:24","pubTimestamp":1733405040,"startTime":"0","endTime":"0","summary":"RocheRHHBY announced that the FDA has accepted its supplemental biologics license application  seeking expanded use of Columvi  for second-line relapsed or refractory (R/R) diffuse large B-cell lymphoma  for review. The eligible population includes DLBCL patients who have received at least one prior line of treatment  and are not candidates for autologous stem cell transplant. A final decision from the regulatory body is expected on July 20, 2025.The STARGLO study is designed as a confirmatory study to convert the accelerated approval of Columvi in the United States and conditional marketing authorization in the EU to full approvals for third-line R/R DLBCL. Roche is also currently evaluating Columvi in combination with Polivy , MabThera/Rituxan, cyclophosphamide, doxorubicin and prednisone in the phaseIII SKYGLO study to treat previou","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/m4HB314mWNtMsu4YAqAJlw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d12eb3cde35a8fdb0f38466dd3f64a4d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/m4HB314mWNtMsu4YAqAJlw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d12eb3cde35a8fdb0f38466dd3f64a4d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-roches-columvi-sbla-132400754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999011175.SGD","SOC","IE00B19Z3581.USD","LU1057294990.SGD","LU1894683348.USD","BK4585","BK4592","BK4007","LU1430594728.SGD","SG9999002224.SGD","BK4568","IE00BLSP4452.SGD","LU0058720904.USD","LU0225284248.USD","LU0985481810.HKD","BK4534","IE00B19Z3B42.SGD","GILD","LU1883839398.USD","LU0053671581.USD","BK4532","LU0321505868.SGD","IE00BBT3K403.USD","IE00B3T34201.USD","03165","BK4583","SG9999001176.USD","BK4566","LU0234572021.USD","SG9999001176.SGD","LU0306806265.USD","LU2087621335.USD","LU1585245621.USD","LU1894683264.USD","BK4599","IE0002270589.USD","LU0109394709.USD","SG9999013999.USD","IE00BLSP4239.USD","LU1023059063.AUD","RHHBY","HALO","LU2468319806.SGD","BK4533","IE00B7SZLL34.SGD","LU0289739699.SGD","LU0868494617.USD","SGXZ57979304.SGD","PFE","LU0321505439.SGD"],"gpt_icon":1}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":127,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null},{"market":"US","date":"2024-02-01","symbol":"RHHBY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"","actualEps":null},{"date":"2023-07-27","symbol":"RHHBY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690444800000,"name":null,"time":"Pre-Market","dateTimestamp":1690430400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-02","recordDate":"2016-03-04","paymentDate":"2016-04-22","value":0.837655,"currency":"USD"},{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.125,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.75,"analysts":8,"updateTime":1745899200000}}}